The INSPIRE-1 and INSPIRE-2 trials are Phase 3 studies assessing the efficacy and safety of tildrakizumab 100 mg (ILUMYA) in adults with active psoriatic arthritis (PsA)
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Vimta Labs has reported total income of Rs. 99.31 crores during the period ended June 30, 2025
The new Zigly center features and offers comprehensive veterinary services
Phosphate-based excipients provide higher bulk densities and enable the reduction of the tablet sizes
This achievement underscores our unwavering commitment to upholding the highest standards of quality, safety, and regulatory compliance
This facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms
The receipt of EIR reaffirms the company's commitment to maintaining global quality standards
Subscribe To Our Newsletter & Stay Updated
